Manufacturing

Manufacturing

R-Pharm’s production designed with account to all latest GMP requirements, which is unprecedented for Russia, especially for the production of aseptic injection drug formulations.

Новости

R-Pharm and AbbVie Announce Launch of Project on Localization of Full-Cycle Production of Inhalation Anesthetic Sevorane (sevoflurane)

news

A global biopharm company AbbVie and a leading Russian pharmaceutical manufacturer R-Pharm announce the start of a project on localization of full-cycle production of inhalation anesthetic Sevorane (sevoflurane), which is included into all the standards of care in surgical nosology and pediatric surgery in particular. The project fosters development of the Russian pharm industry and enables to attain goals and objectives of the state strategy “Pharma 2020” and to carry out the plan on increasing the rate of medications in VED list manufactured in Russia by 2018.

July 22, 2015

R-Pharm Group of Companies Participates in Conference Held by The Moscow Times Named “Localization of Production in Pharm Industry”

R-Pharm Group of Companies Participates in Conference Held by The Moscow Times Named “Localization of Production in Pharm Industry”

On June 30th there took place a conference held by “The Moscow Times” newspaper named “Localization of production in pharm industry”. In the event there took part over 80 delegates. Among them there were chief executives and heads of companies specialized in pharm and chemical industries, logistics operators, representatives of special economic zones and industrial estates as well as leading consulting companies and law firms. In the event there took part Alexander Bykov, Director of Economy in Healthcare of R-Pharm group of companies.

July 6, 2015

R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease

news

In August 2015 R-Pharm group of companies starts patient recruitment for phase II study of genetically engineered preparation RFM-203 (РФМ-203) developed for treatment of cancer metastases to the bones. RFM-203 can become one of the first original biological preparations that was fully developed, manufactured and applied practically by a Russian pharm company.

July 6, 2015

R-Pharm History in Three and a Half Minutes

R-Pharm History in Three and a Half Minutes

The presentation video was made within the framework of the International Final of a prestigious contest “Entrepreneur of the Year” organized by EY company in Monte Carlo in 2015 where Mr. Alexey Repik, Chairman of Board of Directors of R-Pharm group of companies, took part.

July 1, 2015

R-Pharm Group of Companies Introduces New Class Antibiotic in the Market

news

In June 2015 R-Pharm group of companies received marketing authorization ЛП-003046 dd. 18/06/2015 issued by Ministry of Healthcare of the Russian Federation for the innovative lipoglycopeptide antibiotic with the brand name of VIBATIV (international non patented name is telavancin). The product is developed for the treatment of complicated nosocomial infections caused by Gram-positive bacteria including pathogens resistant to other groups of antibiotics.

June 30, 2015
News Archive →